Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service

As part of this process, the Contracting Authority would like to invite interested parties to read and complete our Invitation to Tender within our e-Tendering System Atamis, atamis-1928.my.site.com/s/Welcome ↗. This service will be competed under The Health Care Services (Provider Selection Regime) Regulations 2023 and will not be competed via Public Contract Regulations 2015 or via the Procurement Act 2023.<br/><br/>The Contracting Authority will be using Atamis, the Contracting Authority’s e-Tendering system for this procurement exercise. For further information, the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system.<br/><br/>Only Tenders which pass the applicable compliance checks and all applicable Pass/Fail requirements in Questionnaire 1 – the Basic Selection Criteria Questionnaire in accordance with Document 1 – ITT Instructions, will proceed to Stage 2 evaluation.<br/><br/>Stage 1 (Compliance and Basic Selection Criteria Questionnaire)<br/>Compliance checks will be completed to ensure tenders are completed as per the ITT instructions. The Basic Selection Criteria Questionnaire will evaluate the Basic Selection Criteria. The questions will be evaluated on a Pass/Fail or for information only basis and can be found in Document 3.<br/><br/>Stage 2 (Quality, Social Value and Commercial Envelope)<br/>This will be the evaluation of the Quality and Commercial envelope which contains the Key Criteria questions and can be found in Document 4 (Quality and Social Value Envelope) and Document 5 (Commercial Envelope). Scores from Stage 2 evaluation will form 100% of the final score.<br/><br/>The Key Criteria (as outlined in PSR Regulation 5) for Stage 2 will be evaluated as outlined below:<br/><br/>Stage 2 - Quality & Social Value Envelope - 80%<br/><br/>1. Service model, accountability and pathway operation - 10%<br/><br/>National delivery model, governance, roles/responsibilities, handoffs, escalation and VSPC accountability.<br/><br/>2. Collection packs, sample-taking site interface and logistics - 12% <br/><br/>Consumables, site onboarding, Sample handoff, transport, chain of custody, logistics resilience and exceptions.<br/><br/>3. Laboratory capability, assay control, accreditation and analytical quality - 16%<br/><br/>Laboratory capability, UKAS/ISO 15189, approved PSA assay, IQC/EQA, calibration, validation and analytical consistency.<br/><br/>4. Result reporting, National IT interface, data and management information- 10%<br/><br/>Result transmission, interfaces, acknowledgements, data quality, reconciliation, downtime, MI and reporting.<br/><br/>5. Failsafe, invalid Samples, repeat collection and onward MRI/biopsy coordination - 14%<br/><br/>Failsafe, failed/invalid Samples, repeats, MRI coordination, biopsy/urology handoff, acknowledgement and escalation.<br/><br/>6. Mobilisation, capacity, resilience and business continuity - 8%<br/><br/>Mobilisation, readiness, capacity, testing, resilience, BCP, recovery, transition and exit.<br/><br/>7. Social Value – fair work, sustainable delivery and additional equitable-access benefits – 10%<br/><br/>PSR Key Criteria<br/><br/>In accordance with Regulation 5 of the Health Care Services (Provider Selection Regime) Regulations 2023, the award criteria collectively assess all five PSR Key Criteria as follows:<br/><br/>Quality and Innovation – assessed through Questions 1–6 of the Quality Envelope, including service quality, logistics, laboratory capability, analytical quality, digital/result reporting, Failsafe arrangements, mobilisation, capacity and resilience.<br/><br/>Value – assessed through the Commercial Envelope, weighted at 20%.<br/><br/>Integration, Collaboration and Service Sustainability – assessed principally through Questions 1, 4, 5 and 6, including governance, pathway interfaces, National IT integration, handoffs, onward coordination, capacity, resilience and business continuity.<br/><br/>Improving Access, Reducing Health Inequalities and Facilitating Choice – assessed principally through Questions 2, 5 and 7, including equitable national logistics and access, remote-area arrangements, Failsafe/pathway coordination and additional equitable-access commitments.<br/><br/>Social Value – assessed through Question 7, weighted at 10%.<br/><br/>Stage 2 - Commercial Envelope - 20%<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 or Procurement Act 2023 do not apply to this award.